Development of AL101 (GSK4527226), a progranulin-elevating monoclonal antibody, as a potential treatment for Alzheimer’s disease

Abstract Background Alzheimer’s disease (AD) is characterized by amyloid plaques, tau tangles, and neuronal loss. Progranulin (PGRN) is a secreted immune regulator, lysosomal chaperone, and neuronal survival factor. Genetic polymorphisms that reduce PGRN levels are associated with an increased risk...

Full description

Bibliographic Details

Published in:	Alzheimer’s Research & Therapy
Main Authors:	Balasubrahmanyam Budda, Ananya Mitra, Lovingly Park, Hua Long, Michael Kurnellas, Nga Bien-Ly, William Estacio, Brady Burgess, Grace Chao, Tina Schwabe, Robert Paul, Sara Kenkare-Mitra, Arnon Rosenthal
Format:	Article
Language:	English
Published:	BMC 2025-07-01
Subjects:	AL101 Alzheimer’s disease Clinical trial Monoclonal antibody Neurodegenerative diseases Progranulin
Online Access:	https://doi.org/10.1186/s13195-025-01817-4